Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

Inclusion Criteria: * ≥18 years of age. * Newly diagnosed multiple myeloma. * Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 or 1. * Women of childbearing potential must have a negative serum pregnancy test prior to starting treatment and agree to use a highly effective method of contraception, such as a hormonal method that inhibits ovulation, an intrauterine device, or a vasectomy partner. * Males: agree to use a highly effective contraceptive method, such as a male condom or vasectomy. Exclusion Criteria: * History of previous treatment for MM. * Active central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. * Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) or AL amyloidosis. * Severe active infection secondary to viruses, bacteria or fungi. * Pulmonary disease requiring supplemental oxygen. * History of allogeneic or autologous hematopoietic cell transplantation. * Vaccination with live attenuated virus in the 4 weeks prior to teclistamab administration. * Major surgery during the 2 weeks prior to the first dose or absence of complete recovery from surgery. * Presence of other concomitant malignancy. * Hepatitis B and C virus infection or human immunodeficiency virus (HIV) infection. * Cerebrovascular events or seizures in the last 6 months. * Congestive heart failure class III-IV according to NYHA (New York Heart Association Stage). * Acute myocardial infarction or history of coronary revascularization surgery in the last 6 months. * Women of childbearing age: active pregnancy prior to the first administration of treatment.